Trial Profile
An Observational Cohort Study to Evaluate the Safety and Efficacy of Micardis Tablets Taken Once Daily at 40 mg/Day and 80 mg/Day in Hypertensive Patients Under Real Life Conditions in Usual Clinical Practice.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Apr 2010
Price :
$35
*
At a glance
- Drugs Telmisartan (Primary)
- Indications Essential hypertension
- Focus Therapeutic Use
- Acronyms CONTROL
- Sponsors Boehringer Ingelheim
- 28 Apr 2010 Actual number of patients changed from 757 to 987 as reported by ClinicalTrials.gov.
- 26 Sep 2009 New trial record